Effect of supplementation in treatment of patients with endometrial hyperplasia
Phase 3
- Conditions
- Endometrial hyperplasia.Endometrial hyperplasiaE11.2
- Registration Number
- IRCT201606275623N86
- Lead Sponsor
- Vice chancellor for research, Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Aged 35 to 55 years
Patients with endometrial hyperplasia
informed consent
Exclusion Criteria
Menopausal women
History of cardiovascular disease
Diabetes mellitus
Fasting plasma glucose (FPG) > 126 mg/dL
Consumption of antihyperglycemic agents including metformin
Triglycerides levels > 500 mg/dL
Systolic blood pressure = 160 mmHg
Diastolic blood pressure = 110 mmHg
Untreated thyroid disease
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to treatment. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Sonography.
- Secondary Outcome Measures
Name Time Method